Dyspnoea in patients with advanced cancer: Incidence, causes and treatments

Baines, 1978, Control of other symptoms Ventafridda, 1990, Quality of life assessment during a palliative care programme, Ann Oncol, 1, 415, 10.1093/oxfordjournals.annonc.a057794 Higginson, 1989, Measuring symptoms in terminal cancer: are pain and dyspnoea controlled?, J Royal Soc Med, 82, 264, 10.1177/014107688908200507 Grond, 1994, Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic, J Pain Symptom Manag, 9, 372, 10.1016/0885-3924(94)90174-0 Donnelly, 1995, The symptoms of advanced cancer: identification of clinical and research priorities by assessment of prevalence and severity, J Palliat Care, 11, 27, 10.1177/082585979501100105 Curtis, 1991, Common symptoms in patients with advanced cancer, J Palliat Care, 7, 25, 10.1177/082585979100700205 Heyse-Moore, 1991, How much of a problem is dyspnea in advanced cancer?, Palliat Med, 5, 20, 10.1177/026921639100500105 Ventafridda, 1990, Symptom prevalence and control during cancer patient's last days of life, J Palliat Care, 6, 7, 10.1177/082585979000600303 Twycross, 1986, Control of Alimentary Symptoms in Far Advanced Cancer, 1 Muers, 1993, Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organization Thoracic Group, Thorax, 48, 339, 10.1136/thx.48.4.339 Saunders, 1984, The Management of Terminal Malignant Disease, 113 Reuben, 1986, Dyspnea in terminally ill cancer patients, Chest, 89, 234, 10.1378/chest.89.2.234 Desbiens, 1997, The relationship of nausea and dyspnea to pain in seriously ill patients, Pain, 71, 149, 10.1016/S0304-3959(97)03353-8 Krech, 1991, Symptoms of pancreatic cancer, J Pain Symptom Manag, 6, 360, 10.1016/0885-3924(91)90027-2 Hardy, 1994, Prediction of survival in a Hospital-based Continuing Care Unit, Eur J Cancer, 30A, 284, 10.1016/0959-8049(94)90242-9 Maltoni, 1995, Prediction of survival of patients terminally ill with cancer, Cancer, 75, 2613, 10.1002/1097-0142(19950515)75:10<2613::AID-CNCR2820751032>3.0.CO;2-1 Escalante, 1996, Dyspnea in Cancer Patients, 78, 1314 Ripamonti, 1997, Dyspnea: pathophysiology and assessment, J Pain Symptom Manag, 13, 220, 10.1016/S0885-3924(96)00327-2 Ahmedzai, 1993, Palliation of respiratory symptoms, 349 Congleton, 1995, The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy, Respir Med, 89, 291, 10.1016/0954-6111(95)90090-X Bruera, 1993, Clinical management of cachexia anorexia, 330 Palange, 1995, National state and exercise tolerance in patients with COPD, 107, 1206 Kongragunta, 1995, Dyspnea and diaphragmatic fatigue in patients with chronic obstructive pulmonary disease, Chest, 107, 1206 Arora, 1982, Respiratory muscle strength and maximal voluntary ventilation in undernourished patients, Am Rev Respir Dis, 126, 5 Clark, 1995, Muscle fatigue and dyspnoea in chronic heart failure: two sides of the same coin?, Eur Heart J, 16, 49, 10.1093/eurheartj/16.1.49 Mahler, 1987, Comparison of clinical dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease, Am Rev Respir Dis, 135, 1229, 10.1164/arrd.1987.135.6.1229 Stoller, 1986, Further specification and evaluation of a new clinical index for dyspnea, Am Rev Respir Dis, 134, 1129 Burns, 1969, Disproportionately severe breathlessness in chronic bronchitis, Quart J Med, 151, 277 Burdon, 1994, Chronic lung disease and the perception of breathlessless: a clinical perspective, Eur Respir J, 7, 1342, 10.1183/09031936.94.07071342 Medical Research Council, 1991, Inoperable non-small cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions, Br J Cancer, 63, 265, 10.1038/bjc.1991.62 Cullen, 1993, The MIC regimen in non-small cell lung cancer, Lung Cancer, 9, 81, 10.1016/0169-5002(93)90173-U Hardy, 1989, Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer, Br J Cancer, 60, 764, 10.1038/bjc.1989.355 Fernandez, 1989, Quality of life during chemotherapy in non-small cell lung cancer patients, Acta Oncolog, 28, 29, 10.3109/02841868909111177 Thatcher, 1995, Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumor-related symptoms, Anti-Cancer Drugs, 6, 39, 10.1097/00001813-199512006-00007 Nelson, 1995, Dyspnea with gemcitabine is commonly seen, often disease related, transient and rarely severe, Eur J Cancer, 31(A, 197, 10.1016/0959-8049(95)96199-N Kaye, 1994, Gemcitabine: current status of phase I and II trials, J Clin Oncol, 12, 1527, 10.1200/JCO.1994.12.8.1527 Pavlakis, 1997, Fatal pulmonary toxicity resulting from treatment with gemcitabine, Cancer, 80, 286, 10.1002/(SICI)1097-0142(19970715)80:2<286::AID-CNCR17>3.0.CO;2-Q Anderson, 1985, Subacute pulmonary failure complicating therapy with high dose ara-C in acute leukemia, Cancer, 56, 2181, 10.1002/1097-0142(19851101)56:9<2181::AID-CNCR2820560907>3.0.CO;2-B Shearer, 1994, Pulmonary insufficiency complicating therapy with high dose cytosine arabinoside in five paedriatic patients with relapsed acute myelogenous leukemia, Cancer, 74, 1953, 10.1002/1097-0142(19941001)74:7<1953::AID-CNCR2820740721>3.0.CO;2-E Rivera, 1995, Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy, Am J Clin Oncol, 18/3, 245, 10.1097/00000421-199506000-00012 Varricchio, 1985, Clinical management of superior vena cava syndrome, Heart Lung, 14, 411 Adelstein, 1988, Thromboembolic events in patients with malignant superior vena cava syndrome and the role of anticoagulation, Cancer, 62, 2258, 10.1002/1097-0142(19881115)62:10<2258::AID-CNCR2820621031>3.0.CO;2-I Smith, 1988, Respiratory complications of malignant disease, 319 Sculier, 1985, Superior vena cava obstruction syndrome: recommendations for management, Cancer Treat Rev, 15, 165 Lequaglie, 1997, Malignant obstruction of the superior vena cava and its palliation, J Exp Clin Cancer Res, 16/2, 16 Stock, 1995, Treatment of malignant obstruction of the superior vena cava with the self-expanding Wallstent, Thorax, 50, 1151, 10.1136/thx.50.11.1151 Miche, 1995, Endoluminal HDR brachytherapy in the palliative treatment of patients with the recurrence of a non-small-cell bronchial carcinoma after prior radiotherapy, Strahlenther Onkol, 171, 554 Huber, 1995, Palliative endobronchial brachytherapy for central lung tumors, 107, 463 Cavaliere, 1996, Endoscopic treatment of malignant airway obstructions in 2,008 patients, Chest, 110, 1536, 10.1378/chest.110.6.1536 Aygun, 1995, Treatment of unresectable lung cancer with brachytherapy, World J Surg, 19, 823, 10.1007/BF00299778 Ninane, 1995, Endoscopic management of acute respiratory failure related to tracheobronchial malignancies, Support Care Cancer, 3, 418, 10.1007/BF00364983 Macha, 1995, Endobronchial radiation therapy for obstructing malignancies: ten years' experience with iridium-192 high-dose radiation brachytherapy afterloading technique in 365 patients, Lung, 173, 271, 10.1007/BF00176890 Spinelli, 1993, A new technique of endoscopic implantation of self-expanding mesh stents for inoperable traceho-bronchial malignancies, End Surg, 1, 82 Wilson, 1996, Treatment of large airway obstruction in lung cancer using expandable metal stents inserted under direct vision via the fibreoptic bronchoscope, Thorax, 51, 248, 10.1136/thx.51.3.248 Brutinel, 1987, A two year experience with the neodymium-YAG laser in endobronchial carcinoma, Chest, 91, 159, 10.1378/chest.91.2.159 Petrou, 1994, The management of tracheobronchial obstruction: a review of endoscopic techniques, Eur J Cardiothorac Surg, 8, 436, 10.1016/1010-7940(94)90086-8 Mestitz, 1989, Intrathoracic manifestation of disseminated prostatic adenocarcinoma, Respir Med, 83, 161, 10.1016/S0954-6111(89)80236-7 Sahn, 1987, Malignant pleural effusions, 9, 43 Chernow, 1977, Carcinomatous involvement of the pleura: an analysis of 96 patients, Am J Med, 63, 695, 10.1016/0002-9343(77)90154-1 Miles, 1993, Diagnosis and management of malignant pleural effusion, Cancer Treat Rev, 19, 151, 10.1016/0305-7372(93)90032-M Estenne, 1983, Mechanism of relief of dyspnea after thoracocentesis in patients with pleural effusions, Am J Med, 74, 813, 10.1016/0002-9343(83)91072-0 Walker-Renard, 1994, Chemical pleurodesis for malignant pleural effusions, Ann Intern Med, 120, 56, 10.7326/0003-4819-120-1-199401010-00010 Viallat, 1996, Thoracoscopic talc pudrage pleurodesis for malignant effusions, 110, 1387 Boniface, 1989, Interet du talcage par thoracoscopie dans le traitment symptomatique des pleuresies recidivantes a propos de 302 cas, Rev Mal Respir, 6, 133 Canto, 1985, Pleural effusion of malignant etiology: thoracoscopic use of talc as an effective method of pleurodesis, Med Clin, 84, 806 Ladjimi, 1989, Resultats du talcage pleural sous thoracoscopie au cours des pleuresies neoplasiques, Rev Mal Respir, 6, 147 Sanchez-Armengol, 1993, Survival and talc pleurodesis in metastatic pleural carcinoma revisited: report of 125 cases, Chest, 104, 1482, 10.1378/chest.104.5.1482 Weissberg, 1993, Talc pleurodesis: experience with 360 patients, J Thorac Cardiovasc Surg, 106, 689, 10.1016/S0022-5223(19)33712-2 Petrou, 1995, Management of recurrent malignant pleural effusions, 75, 801 Ponn, 1991, Pleuroperitoneal shunting for intractable pleural effusions, Ann Thorac Surg, 51, 605, 10.1016/0003-4975(91)90319-L Tsang, 1990, Pleuroperitoneal shunt for recurrent malignant pleural effusions, Thorax, 45, 369, 10.1136/thx.45.5.369 Little, 1988, Pleuroperitoneal shunting, Ann Surg, 208, 443, 10.1097/00000658-198810000-00006 Roukema, 1990, Ascites after pleuroperitoneal shunting, Cancer, 66, 675, 10.1002/1097-0142(19900815)66:4<675::AID-CNCR2820660413>3.0.CO;2-3 Findlay, 1988, Cardiac complications of malignant disease, 283 Press, 1987, Management of malignant pleural effusion and tamponade, J Am Med Assoc, 257, 1088, 10.1001/jama.257.8.1088 Mauch, 1985, Treatment of malignant pericardial effusions, 2141 Wilding, 1988, Tumours of the heart and pericardium, Cancer Treat Rev, 15, 165, 10.1016/0305-7372(88)90001-1 Kvale, 1991, The cancer patient with dyspnea: unusual cause?, Mayo Clin Proc, 66, 215, 10.1016/S0025-6196(12)60496-0 Anderlini, 1995, Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia, J Clin Oncol, 13, 2827, 10.1200/JCO.1995.13.11.2827 Yano, 1996, Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer, Jpn Circ J, 60, 185, 10.1253/jcj.60.185 Shan, 1996, Anthracycline-induced cardiotoxicity, Ann Intern Med, 125, 47, 10.7326/0003-4819-125-1-199607010-00008 Lund, 1996, Cardiopulmonary sequelae after treatment for Hodgkin's disease: increased risk in females?, Ann Oncol, 7, 257, 10.1093/oxfordjournals.annonc.a010569 Ford, 1996, Phase I trial etoposide, doxorubicina and cisplatin (EAP) in combination with GM-CSF, Eur J Cancer, 32A, 631, 10.1016/0959-8049(95)00602-8 Dreicer, 1997, Vinblastine, isofosfamide, and gallium nitrate—an active new regimen in patients with advanced carcinoma of the urothelium, 79, 110 Pizzo, 1993, Infections in the cancer patient, 2, 2292 Bruera, 1993, The effects of oxygen on the intensity of dyspnea in hypoxemic terminal cancer patients, Lancet, 342, 13, 10.1016/0140-6736(93)91880-U Bruera, 1992, Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: the use of the N of 1 randomized controlled trial, J Pain Symptom Manag, 7, 365, 10.1016/0885-3924(92)90091-U Booth, 1996, Does oxygen help dyspnea in patients with cancer?, Am J Respir Crit Care Med, 153, 1515, 10.1164/ajrccm.153.5.8630595 Restrick, 1992, Ambulatory oxygen in chronic heart failure, Lancet, 340, 1192, 10.1016/0140-6736(92)92893-K Moore, 1992, Effects of increased inspired oxygen concentrations on exercise performance in chronic heart failure, Lancet, 339, 850, 10.1016/0140-6736(92)90288-E Swinburn, 1991, Symptomatic benefit of supplemental oxygen in hypoxemic patients with chronic lung disease, Am Rev Respir Dis, 143, 913, 10.1164/ajrccm/143.5_Pt_1.913 Davidson, 1988, Supplemental oxygen and exercise ability in chronic obstructive airways disease, Thorax, 43, 965, 10.1136/thx.43.12.965 Woodcock, 1981, Oxygen relieves breathlessness in “pink puffers”, Lancet, 907, 10.1016/S0140-6736(81)91612-3 Dean, 1992, Oxygen may improve dyspnea and endurance in patients with chronic obstructive pulmonary disease and only mild hypoxemia, Am Rev Respir Dis, 146, 941, 10.1164/ajrccm/146.4.941 Liss, 1988, The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease, Am Rev Respir Dis, 137, 1285, 10.1164/ajrccm/137.6.1285 Doll, 1985, Neoplasia and the erythron, J Clin Oncol, 3, 429, 10.1200/JCO.1985.3.3.429 Case, 1993, Recombinant human erythropoietin therapy for anemic patients on combination chemotherapy, J Natl Cancer, 85, 801, 10.1093/jnci/85.10.801 Henry, 1994, Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies, Semin Oncol, 21, 21 Del Mastro, 1997, Randomized Phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia, J Clin Oncol, 15, 2715, 10.1200/JCO.1997.15.7.2715 Ludwig, 1995, Recombinant human erythropoietin for the correction of cancer associated anemia with a without concomitant cytotoxic chemotherapy, Cancer, 76, 2319, 10.1002/1097-0142(19951201)76:11<2319::AID-CNCR2820761121>3.0.CO;2-U Monti, 1996, Use of red blood cell transfusions in terminally ill cancer patients admitted to a Palliative Care Unit, J Pain Symptom Manag, 12, 18, 10.1016/0885-3924(96)00044-9 Gleeson, 1995, Blood transfusion and its benefits in palliative care, Palliative Medicine, 9, 307, 10.1177/026921639500900405 Mozes, 1989, Evaluation of the appropriateness of blood and blood product transfusion using preset criteria, Transfusion, 29, 473, 10.1046/j.1537-2995.1989.29689318442.x Elwood, 1973, Evluation of the clinical importance of anemia, Am J Clin Nutr, 26, 958, 10.1093/ajcn/26.9.958 Viteri, 1974, Anaemia and physical work capacity, Clin Haematol, 3, 609 Wachtel, 1985, The use of transfusion in terminal cancer patients, 25, 278 Frew, 1993, Clinical pharmacology of asthma, 46, 847 Ziment, 1990, Pharmacologic therapy of obstructive airway disease, Clin Chest Med, 11, 461, 10.1016/S0272-5231(21)00712-7 Celli, 1995, Comprehensive outpatient management of COPD, Am J Respir Crit Care Med, 152, S84, 10.1164/ajrccm/152.5_Pt_2.S84 Thompson, 1996, Controlled trial of oral prednisone in outpatient with acute COPD exacerbation, Am J Respir Crit Care Med, 154, 407, 10.1164/ajrccm.154.2.8756814 Ferguson, 1990, Effect of corticosteroids on respiratory muscle histopathology, Am Rev Respir Dis, 142, 1047, 10.1164/ajrccm/142.5.1047 Mahler, 1985, Sustained-release theophylline reduced dyspnea in nonreversible obstructive airway disease, Am Rev Respir Dis, 131, 22 Aubier, 1981, Aminophylline improves diaphragmatic contractility, N Engl J Med, 305, 249, 10.1056/NEJM198107303050503 Wittmann, 1982, The effect of caffeine on diaphragmatic muscle force in normal hamsters, Am Rev Respir Dis, 126, 499 Murciano, 1984, Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease, N Engl J Med, 311, 349, 10.1056/NEJM198408093110601 Bruera, 1993, Subcutaneous morphine for dyspnea in cancer patients, Annals Int Med, 119, 906, 10.7326/0003-4819-119-9-199311010-00007 Bruera, 1990, The effects of morphine on the dyspnea of terminal cancer patients, J Pain Symptom Manag, 5, 341, 10.1016/0885-3924(90)90027-H Cohen, 1991, Continuous intravenous infusion of morphine for severe dyspnea, Southern Med J, 84, 229, 10.1097/00007611-199102000-00019 Ventafridda, 1990, Control of dyspnea in advanced cancer patients, Chest, 98, 1544, 10.1378/chest.98.6.1544a Browning, 1988, Effect of hydrocodone on dyspnea, respiratory drive and exercise performance in adult patients with cystic fibrosis, Am Rev Respir Dis, 137, 305 Woodcock, 1981, Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases, N Engl J Med, 305, 1611, 10.1056/NEJM198112313052703 Johnson, 1983, Dihydrocodeine for breathlessness in “pink puffers”, Br Med J, 286, 675, 10.1136/bmj.286.6366.675 Robin, 1986, Risk-benefit analysis in chest medicine, 90, 889 Light, 1989, Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease, Am Rev Respir Dis, 139, 126, 10.1164/ajrccm/139.1.126 Rice, 1987, Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction, Br J Dis Chest, 81, 287, 10.1016/0007-0971(87)90163-X Eiser, 1991, Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the “pink puffer” syndrome, Eur Respir J, 4, 926 Lane, 1983, The clinical presentation of chest disease, 1539 Santiago, 1985, Opioids and breathing, J Appl Physiol, 59, 1675, 10.1152/jappl.1985.59.6.1675 Florez, 1983, Focusing on the respiratory actions of opioids, Trends Pharmacol Sci, 4, 470, 10.1016/0165-6147(83)90496-0 Hughes, 1981, Peripheral opioid receptor mechanisms, Trends Pharmacol Sci, 2, 21, 10.1016/0165-6147(81)90249-2 McQueen, 1983, Opioid peptide interactions with respiratory and circulatory systems, Br Med Bull, 39, 77, 10.1093/oxfordjournals.bmb.a071795 Johansson, 1988, Modulation of the airways excitatory neuronal pathways via alpha2 adrenoceptors and opioid receptors, Acta Physiol Scand, 134, 29 Belvisi, 1990, Modulation of cholinergic neurotransmission in guinea-pig airways by opioids, Br J Pharmacol, 100, 131, 10.1111/j.1476-5381.1990.tb12064.x Bellofiore, 1990, Endogenous opioids modulate the increase in ventilatory output and dyspnea during severe acute bronchoconstriction, Am Rev Respir Dis, 142, 812, 10.1164/ajrccm/142.4.812 Rogers, 1989, Opioid inhibition of neurally mediated mucous secretion in human bronchi, Lancet, 1, 930, 10.1016/S0140-6736(89)92509-9 Davis, 1992, Low systemic bioavailability of nebulized morphine: potential therapeutic role for the relieve of dyspnea, 11, A359 Masood, 1996, Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects, Br J Clin Pharmacol, 41, 250, 10.1111/j.1365-2125.1996.tb00192.x Farncombe, 1994, The use of nebulized opioids for breathlessness: a chart review, Palliat Med, 8, 306, 10.1177/026921639400800406 Davis, 1996, Single dose randomized controlled trial of nebulized morphine in patients with cancer related breathlessness, Palliat Med, 10, 64 Young, 1989, Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease, Thorax, 44, 387, 10.1136/thx.44.5.387 Weil, 1975, Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man, N Engl J Med, 292, 1103, 10.1056/NEJM197505222922106 Bourke, 1989, The steady state and rebreathing methods compared during morphine administration in humans, J Physiol, 419, 509, 10.1113/jphysiol.1989.sp017883 Santiago, 1979, Effects of morphine on ventilatory response to exercise, J Appl Physiol, 47, 112, 10.1152/jappl.1979.47.1.112 Davis, 1994, Effect of nebulised morphine and morphine-6-glucuronide on exercise endurance in patients with chronic obstructive pulmonary disease, Thorax, 49, 393 Masood, 1995, Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease, Thorax, 50, 629, 10.1136/thx.50.6.629 Beauford, 1993, Effects of nebulized morphine sulfate on the exercise tolerance on the ventilatory limited COPD patient, Chest, 104, 175, 10.1378/chest.104.1.175 Craven, 1991, Buspirone for anxiety disorders in patients with severe lung disease, Lancet, 338, 249, 10.1016/0140-6736(91)90382-Y Stark, 1981, Methods to assess breathlessness in healthy subjects: a critical evaluation and application to analyse the acute effects of diazepam and promethazine on breathlessness induced by exercise or by exposure to raised levels of carbon dioxide, Clin Sci, 61, 429, 10.1042/cs0610429 O'Neill, 1985, Chlorpromazine—a specific effect on breathlessness?, Br J Clin Pharmac, 19, 793, 10.1111/j.1365-2125.1985.tb02716.x Woodcock, 1981, Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers, Br Med J, 283, 343, 10.1136/bmj.283.6287.343 Man, 1986, Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease, Chest, 90, 832, 10.1378/chest.90.6.832 Mitchell-Heggs, 1980, Diazepam in the treatment of dyspnoea in the “pink puffer” syndrome, Quart J Med New Series, XLIX, 9 Light, 1996, Effect of 30 mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD, Chest, 109, 975, 10.1378/chest.109.4.975